Patrys picks up third US patent for PAT-SM6
19 June, 2014 by Dylan Bushell-EmblingPatrys (ASX:PAB) has been awarded a third US patent covering its cancer treatment candidate PAT-SM6, which is in clinical trials as a treatment for multiple myeloma.
Novogen, CanTx establish proof of concept for Trx-1
19 June, 2014 by Dylan Bushell-EmblingNovogen (ASX:NRT) and its CanTx JV have published preclinical data supporting the potential of Trx-1, injected into the peritoneal cavity, as a first-line therapy for ovarian cancer.
Atomo wins Best In Show at MDEA
12 June, 2014 by Dylan Bushell-EmblingAtomo Diagnostics' HIV blood test, AtomoRapid HIV, has been named Best In Show at the Medical Design Excellence Awards.
NHMRC awards for excellence
12 June, 2014This year's National Health and Medical Research Council's prizes for excellence in health and medical research have been announced.
Alchemia aims to report on mCRC trial in Q3
10 June, 2014 by Dylan Bushell-EmblingAlchemia (ASX:ACL) now expects top-line results from its phase III trial of HA-Irinotecan in colorectal cancer to be ready in Q3, and aims to file FDA and EMA submissions in 1H15.
Immunotherapy shows promise in treating brain cancer
05 June, 2014Combining standard treatment for recurrent glioblastoma multiforme with immune-based therapies holds promise for patients with this aggressive disease.
Viralytics presents more strong Cavatak trial data
05 June, 2014 by Dylan Bushell-EmblingViralytics (ASX:VLA) announced that Cavatak has to date generated an overall response rate of 26% during a phase II melanoma trial and has demonstrated synergy with mAb therapy during preclinical research.
CVac boosts OS in second-remission ovarian cancer
03 June, 2014 by Dylan Bushell-EmblingData from a phase II trial of Prima BioMed's (ASX:PRR) CVac show that the treatment has had a positive effect on overall survival in ovarian cancer patients in second-line remission.
Supporting Indigenous health
03 June, 2014A $10 million philanthropic gift will be used to establish a Poche Centre for Indigenous Health at the University of Melbourne.
Virax completes purchase of Pathway Oncology
02 June, 2014 by Dylan Bushell-EmblingVirax Holdings (ASX:VHL) has closed the deal to acquire Pathway Oncology, and with it an exclusive licence to a first-in-class cancer therapeutic candidate.
Patient responds well to Patrys's PAT-SM6
29 May, 2014 by Dylan Bushell-EmblingA patient with relapsed multiple myeloma responded well to a combination of Patrys's (ASX:PAB) PAT-SM6 and a proteosome inhibitor, which bodes well for an upcoming trial.
Sienna reagent and cancer biomarker registered with FDA
29 May, 2014The US FDA has registered the lead product of Melbourne-based biotech company Sienna Cancer Diagnostics - the antibody SCD-A7.
Novogen to test SBPs in prostate cancer
27 May, 2014 by Dylan Bushell-EmblingNovogen (ASX:NRT) has identified a number of super-benzopyran (SBP) compounds with a potent effect against prostate cancer cells in vitro, and aims to trial the lead candidate in 2015.
Prima's US patent for CVac allowed
26 May, 2014 by Dylan Bushell-EmblingThe US patent office has granted Prima BioMed a Notice of Allowance covering a patent application protecting cancer treatment candidate CVac.
IST raising $5m for cancer trial, ASX listing
21 May, 2014 by Dylan Bushell-EmblingImmune System Therapeutics (IST) has announced plans to place up to $5m in new shares, to raise funds for a phase IIb multiple myeloma trial and an ASX listing in the third quarter.
